Botulinum Toxin Injections
J15 · Effective Feb 22, 2026
22 active Medicare policies list J0588, and 31 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J15 · Effective Feb 22, 2026
J6 · Effective Feb 22, 2026
JK · Effective Feb 22, 2026
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Feb 22, 2026
JM · Effective Feb 22, 2026
J5 · Effective Feb 22, 2026
J8 · Effective Feb 22, 2026
J9 · Effective Oct 1, 2015
31 policies from 14 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J0588 |
|---|---|---|
| Dry Eyes | Jul 11, 2023 | Covered |
| Headaches: Invasive Procedures | Feb 20, 2024 | Covered |
| Levator Syndrome Treatments | Sep 19, 2023 | Covered |
| Plantar Fasciitis Treatments | Apr 26, 2023 | Covered |
| Rosacea | Aug 10, 2023 | Covered |
| Spasticity Management | Jun 21, 2023 |
JH · Effective Mar 21, 2021
JL · Effective Mar 21, 2021
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
National · Effective Apr 9, 2026
J9 · Effective Nov 9, 2025
JH · Effective Nov 9, 2025
National · Effective Apr 9, 2026
National · Effective Sep 6, 2026
JL · Effective Sep 6, 2026
| Covered |
| Tinnitus Treatments | Feb 16, 2024 | Covered |
|---|
| Trigeminal Neuralgia: Treatments | Feb 15, 2024 | Covered |
|---|
| Vocal Cord Paralysis / Insufficiency Treatments | May 5, 2023 | Covered |
|---|
| Policy | Effective | Status of J0588 |
|---|---|---|
| IncobotulinumtoxinA (Xeomin) | Sep 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| IncobotulinumtoxinA (Xeomin) | Dec 1, 2018 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| IncobotulinumtoxinA (Xeomin) | Aug 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| IncobotulinumtoxinA (Xeomin) | Oct 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| IncobotulinumtoxinA (Xeomin) | Sep 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Xeomin (incobotulinumtoxinA) | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Xeomin (incobotulinumtoxinA) | Aug 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Xeomin (incobotulinumtoxinA) | Aug 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Xeomin (incobotulinumtoxinA) | Aug 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum toxins: abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), onabotulinumtoxinA (Botox), and rimabotulinumtoxinB (Myobloc) – Minnesota Health Care Programs | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Botulinum toxins: abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), onabotulinumtoxinA (Botox), rimabotulinumtoxinB (Myobloc), and daxibotulinumtoxinA-lanm (Daxxify) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum Toxin | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum Toxin | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum Toxin | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum Toxin | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J0588 |
|---|---|---|
| IncobotulinumtoxinA(Xeomin) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0588 |
|---|---|---|
| IncobotulinumtoxinA (Xeomin); CP.PHAR.231 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Xeomin (incobotulinumtoxinA) Listed in Moda Health's provider indexes for Oregon, Alaska, Idaho, Texas. The document does not establish the member's state or line of business. | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum Toxins A and B | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum Toxins A and B | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Botulinum Toxins A and B | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J0588 |
|---|---|---|
| Treatment of Temporomandibular Joint (TMJ) | Not recorded | Covered |